Skip to main content
Top
Published in: Supportive Care in Cancer 11/2013

01-11-2013 | Original Article

Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation

Authors: Tove Godskesen, Peter Nygren, Karin Nordin, Mats Hansson, Ulrik Kihlbom

Published in: Supportive Care in Cancer | Issue 11/2013

Login to get access

Abstract

Background

In cancer, phase 1 clinical trials on new drugs mostly involve patients with advanced disease that is unresponsive to standard therapy. The purpose of this study was to explore the difficult ethical problems related to patient information and motives for participation in such trials.

Method

A descriptive and explorative qualitative design was used. Fourteen cancer patients from three different phase 1 trials in end-stage cancer were interviewed. The interviews were analysed using qualitative content analysis.

Results

The patients expressed unrealistic expectations of therapeutic benefit and inadequate understanding of the trials’ purpose, so-called therapeutic misconception. However, they reported a positive attitude towards participation. Thus, the patients valued the close and unique medical and psychological attention they received by participating. Participation also made them feel unique and notable.

Conclusions

Patients with end-stage cancer participating in phase 1 clinical trials are unaware of the very small potential for treatment benefit and the risk of harm. Trial participation may offer hope and social–emotional support and a strategy for coping with the emotional stress associated with advanced cancer and may, consequently, improve emotional well-being.
Literature
1.
go back to reference Appelbaum PS, Roth LH, Lidz C (1982) The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 5:319–329PubMedCrossRef Appelbaum PS, Roth LH, Lidz C (1982) The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 5:319–329PubMedCrossRef
2.
go back to reference Beauchamp TL, Childress JF (2009) Principles of biomedical ethics. Oxford University Press, New York Beauchamp TL, Childress JF (2009) Principles of biomedical ethics. Oxford University Press, New York
3.
go back to reference Cohen L, de Moor C, Amato RJ (2001) The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial. Cancer 91:1949–1955PubMedCrossRef Cohen L, de Moor C, Amato RJ (2001) The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial. Cancer 91:1949–1955PubMedCrossRef
4.
go back to reference Cox K (2000) Enhancing cancer clinical trial management: recommendations from a qualitative study of trial participants’ experiences. Psychooncol 9:314–322CrossRef Cox K (2000) Enhancing cancer clinical trial management: recommendations from a qualitative study of trial participants’ experiences. Psychooncol 9:314–322CrossRef
5.
go back to reference Cox K (2002) Informed consent and decision-making: patients’ experiences of the process of recruitment to phases I and II anti-cancer drug trials. Patient Educ Couns 46:31–38PubMedCrossRef Cox K (2002) Informed consent and decision-making: patients’ experiences of the process of recruitment to phases I and II anti-cancer drug trials. Patient Educ Couns 46:31–38PubMedCrossRef
6.
go back to reference Daugherty CK (1999) Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol 17:1601–1617PubMed Daugherty CK (1999) Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol 17:1601–1617PubMed
7.
go back to reference Daugherty CK, Banik DM, Janish L, Ratain MJ (2000) Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB 22:6–14PubMedCrossRef Daugherty CK, Banik DM, Janish L, Ratain MJ (2000) Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB 22:6–14PubMedCrossRef
8.
go back to reference Eriksson K (2001) Vårdvetenskap som akademisk disciplin. (Health care science as an academic discipline). Åbo Akademi University, Turku Eriksson K (2001) Vårdvetenskap som akademisk disciplin. (Health care science as an academic discipline). Åbo Akademi University, Turku
9.
go back to reference Fussenich LM, Desar IM, Peters ME, Teerenstra S, van der Graaf WT, Timmer-Bonte JN, van Herpen CM (2011) A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer 47:1152–1160PubMedCrossRef Fussenich LM, Desar IM, Peters ME, Teerenstra S, van der Graaf WT, Timmer-Bonte JN, van Herpen CM (2011) A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer 47:1152–1160PubMedCrossRef
11.
go back to reference Graneheim UH, Lundman B (2004) Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 24:105–112PubMedCrossRef Graneheim UH, Lundman B (2004) Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 24:105–112PubMedCrossRef
12.
go back to reference Han C, Braybrooke JP, Deplanque G, Taylor M, Mackintosh D, Kaur K, Samouri K, Ganesan TS, Harris AL, Talbot DC (2003) Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Brit J Cancer 89:1166–1171PubMedCrossRef Han C, Braybrooke JP, Deplanque G, Taylor M, Mackintosh D, Kaur K, Samouri K, Ganesan TS, Harris AL, Talbot DC (2003) Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Brit J Cancer 89:1166–1171PubMedCrossRef
13.
go back to reference Horng S, Emanuel EJ, Wilfond B, Rackoff J, Martz K, Grady C (2002) Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 347:2134–2140PubMedCrossRef Horng S, Emanuel EJ, Wilfond B, Rackoff J, Martz K, Grady C (2002) Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 347:2134–2140PubMedCrossRef
14.
go back to reference Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magne N, Pignon JP, Vassal G, Armand JP, Soria JC (2008) Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19:787–792PubMedCrossRef Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magne N, Pignon JP, Vassal G, Armand JP, Soria JC (2008) Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19:787–792PubMedCrossRef
15.
go back to reference Jenkins V, Solis-Trapala I, Langridge C, Catt S, Talbot DC, Fallowfield LJ (2011) What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. J Clin Oncol 29:61–68PubMedCrossRef Jenkins V, Solis-Trapala I, Langridge C, Catt S, Talbot DC, Fallowfield LJ (2011) What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. J Clin Oncol 29:61–68PubMedCrossRef
16.
go back to reference Kahneman D, Tversky A (1979) Prospect theory—analysis of decision under risk. Econometrica 47:263–291CrossRef Kahneman D, Tversky A (1979) Prospect theory—analysis of decision under risk. Econometrica 47:263–291CrossRef
17.
go back to reference Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H (2008) Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics 3:57–68PubMedCrossRef Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H (2008) Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics 3:57–68PubMedCrossRef
18.
go back to reference Kvale S (1997) Den kvalitativa forskningsintervjun. Studentlitteratur, Lund Kvale S (1997) Den kvalitativa forskningsintervjun. Studentlitteratur, Lund
19.
go back to reference Kvale S (2007) Doing interviews. Sage, Thousand Oaks Kvale S (2007) Doing interviews. Sage, Thousand Oaks
20.
go back to reference Le Tourneau C, Dieras V, Tresca P, Cacheux W, Paoletti X (2010) Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target Oncol 5:65–72PubMedCrossRef Le Tourneau C, Dieras V, Tresca P, Cacheux W, Paoletti X (2010) Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target Oncol 5:65–72PubMedCrossRef
21.
go back to reference Mcgraw JG (1995) Loneliness, its nature and forms—an existential perspective. Man World 28:43–64CrossRef Mcgraw JG (1995) Loneliness, its nature and forms—an existential perspective. Man World 28:43–64CrossRef
22.
go back to reference Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB, Castel L, Corbett S, Diefenbach M, Gaskin D, Li Y, Manne S, Marshall J, Rowland JH, Slater E, Sulmasy DP, Van Echo D, Washington S, Schulman KA (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician–patient communication. J Clin Oncol 21:2589–2596PubMedCrossRef Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB, Castel L, Corbett S, Diefenbach M, Gaskin D, Li Y, Manne S, Marshall J, Rowland JH, Slater E, Sulmasy DP, Van Echo D, Washington S, Schulman KA (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician–patient communication. J Clin Oncol 21:2589–2596PubMedCrossRef
23.
go back to reference Moore S (2001) A need to try everything: patient participation in phase I trials. J Adv Nurs 33:738–747PubMedCrossRef Moore S (2001) A need to try everything: patient participation in phase I trials. J Adv Nurs 33:738–747PubMedCrossRef
24.
go back to reference Ohlen J (2002) Practical wisdom: competencies required in alleviating suffering in palliative care. J Palliat Care 18:293–299PubMed Ohlen J (2002) Practical wisdom: competencies required in alleviating suffering in palliative care. J Palliat Care 18:293–299PubMed
25.
go back to reference Patton MQ (2002) Qualitative research and evaluation methods. Sage, London Patton MQ (2002) Qualitative research and evaluation methods. Sage, London
26.
go back to reference Saeteren B, Lindstrom UA, Naden D (2011) Latching onto life: living in the area of tension between the possibility of life and the necessity of death. J Clin Nurs 20:811–818PubMedCrossRef Saeteren B, Lindstrom UA, Naden D (2011) Latching onto life: living in the area of tension between the possibility of life and the necessity of death. J Clin Nurs 20:811–818PubMedCrossRef
27.
go back to reference Stolberg SG (2000) Teenager’s death is shaking up field of human gene-therapy experiments. New York Times, New York Stolberg SG (2000) Teenager’s death is shaking up field of human gene-therapy experiments. New York Times, New York
28.
go back to reference Sulmasy DP, Astrow AB, He MK, Seils DM, Meropol NJ, Micco E, Weinfurt KP (2010) The culture of faith and hope patients’ justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer 116:3702–3711PubMedCrossRef Sulmasy DP, Astrow AB, He MK, Seils DM, Meropol NJ, Micco E, Weinfurt KP (2010) The culture of faith and hope patients’ justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer 116:3702–3711PubMedCrossRef
Metadata
Title
Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation
Authors
Tove Godskesen
Peter Nygren
Karin Nordin
Mats Hansson
Ulrik Kihlbom
Publication date
01-11-2013
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1891-7

Other articles of this Issue 11/2013

Supportive Care in Cancer 11/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine